Company Profile
Becton, Dickinson and Company (trading as BD) is a US-based manufacturer of medical devices and medication management systems, headquartered in Franklin Lakes, New Jersey, USA. Founded in 1897, the company operates as an independent publicly traded entity listed on the NYSE: BDX, serving healthcare institutions in over 190 countries with more than 60,000 employees.
Core Products & Technologies
Medical Essentials
• BD Vacutainer: Safety-engineered blood collection systems for specimen integrity
• BD SafetyGlide: Needles with passive safety shields to prevent needlestick injuries
• BD Emerald: Syringes with robust design for general-purpose injection and aspiration
Interventional
• BD CentroVena One: All-in-one central venous catheter insertion system launched in 2026
• Liverty TIPS Stent Graft: Transjugular intrahepatic portosystemic shunt for portal hypertension
• Revello Vascular Covered Stent: Peripheral vascular stent with CE Mark for iliac artery treatment
Connected Care
• BD Alaris Infusion System: Smart pumps with Guardrails suite for medication error reduction
• BD Pyxis Pro: AI-enabled automated dispensing cabinet with RFID and illuminated bins
• BD Incada Platform: Cloud-connected analytics for enterprise medication inventory visibility
Biopharma Systems
• BD Hypak: Prefillable syringes and injectable drug delivery systems for biologics
• BD Neopak: Glass prefillable syringes for sensitive biologic drug formulations
Market Position & Certifications
Becton Dickinson holds a global leadership position in the medical device and infusion therapy market, competing with Medtronic and Stryker. Key strengths include:
• 129+ years of US medtech engineering heritage
• Safety-engineered devices: Passive needlestick prevention and antimicrobial catheter coatings
• Regulatory compliance: CE marked, FDA cleared, ISO 13485 certified globally
• Global service network: Localized technical support across major markets
Corporate Timeline
1897 — Founded in New Jersey by Maxwell Becton and Fairleigh Dickinson
2015 — Expanded infusion and medication management capabilities via CareFusion acquisition
2017 — Entered interventional medicine through C. R. Bard acquisition
2022 — Spun off Diabetes Care business into Embecta Corporation
2026 — Completed separation of Biosciences & Diagnostic Solutions to Waters, becoming pure-play medtech; launched CentroVena One in the U.S.
Target Markets & Applications
• Hospital Acute Care: Alaris infusion and Pyxis medication management systems
• Operating Rooms & Interventional Suites: Surgical, vascular and urology devices
• Pharmaceutical Manufacturing: Prefillable syringes and biologic drug delivery platforms
• Clinical Laboratories: Specimen collection and safety-engineered sharps disposal
Contact Information
Global Headquarters
Address: 1 Becton Drive, Franklin Lakes, New Jersey 07417, USA
Phone: +1 201.847.6800
Website: www.bd.com
Investor Relations
Stock: NYSE: BDX
Website: investors.bd.com
